Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase 2 safety study of apixaban versus warfarin or heparin in children with congenital or acquired heart disease requiring chronic anticoagulation
MOH_2017-07-25_000456Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apixaban, warfarin and enoxaparin (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety of apixaban compared with vitamin K antagonist or subcutaneous heparin. Started May 2017; status: completed.
02
Drugs
apixabanwarfarinenoxaparin
Beyond the preview
Go deeper on MOH_2017-07-25_000456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-25_000456.